Table 5.

Risk of myocardial infarction with CABG compared to PCI

Group	Crude HR	95% CI	P Value	Adjusted HR	95% CI	P Value
Overall (n=3981)	0.90	0.75, 1.07	0.23	0.88	0.73, 1.05	0.16
Preserved kidney Function (n=3459)	0.98	0.81, 1.19	0.87	0.97	0.80, 1.17	0.72
Stage 3-5 CKD (n=522)	0.49	0.30, 0.81	0.01	0.49	0.29, 0.82	0.01
Stage 3a CKD (n=388)	0.68	0.37, 1.27	0.24	0.71	0.36, 1.39	0.31
Stage 3b-5CKD (n=134)	0.27	0.11, 0.66	0.004	0.23	0.09, 0.58	0.002
CKD with multi-vessel disease* (n=416)	0.45	0.26, 0.79	0.01	0.43	0.24, 0.76	0.004
CKD with single vessel disease* (n=106)	0.71	0.20, 2.47	0.59	1.09	0.24, 4.86	0.91
CKD proximal LAD disease* (n=338)	0.39	0.19, 0.80	0.01	0.39	0.18, 0.82	0.01
CKD without proximal LAD disease* (n=183)	0.64	0.31, 1.33	0.23	0.74	0.34, 1.64	0.46

All models were stratified by trial. Multivariable models adjusted for treatment, age, diabetes, prior myocardial infarction, proximal left anterior descending artery disease, ejection fraction <40%, prior revascularization, and multi-vessel.

^*To avoid model overspecification, these subgroup models did not include terms for multi-vessel disease or proximal LAD disease, respectively. CKD-chronic kidney disease. LAD-left anterior descending artery